Scarica l'app Stockscreener
29.45
2.51%
0.72
Pre-mercato:
29.44
-0.010
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Genmab Adr Borsa (GMAB) Ultime notizie
Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC - Defense World
Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies - GlobeNewswire Inc.
Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High Following Analyst Upgrade - Defense World
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Foresight Group Ltd Liability Partnership Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Vident Advisory LLC Buys Shares of 12,377 Genmab A/S Sponsored ADR $GMAB - MarketBeat
Scientech Research LLC Increases Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighStill a Buy? - MarketBeat
Northern Trust Corp Raises Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by Alliancebernstein L.P. - MarketBeat
Graham Capital Management L.P. Acquires 16,035 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cubist Systematic Strategies LLC Grows Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Orbis Allan Gray Ltd Has $111.82 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Synovus Financial Corp Takes $633,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Tema Etfs LLC Boosts Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Stock Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research - Defense World
IBD Rating Upgrades: MINISO Group Holding ADR Flashes Improved Technical Strength - inkl
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
IBD Rating Upgrades: Applied Indl Techs Shows Improved Relative Price Strength - inkl
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
IBD Rating Upgrades: HCA Healthcare Shows Improved Technical Strength - inkl
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World
What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - The Globe and Mail
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Lessened by Cerity Partners LLC - Defense World
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - The Globe and Mail
0.45%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):